Life Technologies has named Paul Billings its chief medical officer, a newly created position that aims to expand the use of genomic technologies in clinical settings.
Billings joins Life Technologies from the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in Silicon Valley, where he served as director and chief scientific officer. Currently, he serves as a member of the United States Department of Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society. He has also been the founder or chief executive officer of companies including GeneSage, Omicia and Cellective Dx. He holds an MD from Harvard Medical School and a PhD in immunology, also from Harvard University.
Complete Genomics has announced changes to its board of directors.
Robert Wall joined the company's board of directors in September. Wall is the founder and president of On Point Developments, a venture management and investment company. He was also the founder and, from 2000 to 2006, the chairman of the board of directors of Airgo Networks, a wi-fi networking systems company that was acquired by Qualcomm in 2006. He received a BA in economics from DePauw University and an MBA from Harvard Business School.
The company has also combined the positions of chairman of the board of directors and chief executive officer. Cliff Reid is serving in the combined role. He is also a founder of Complete Genomics and its president.
Michael Rubin, who has been a member of the board of directors since August, will step down following the company's IPO. Rubin has been a financial analyst at Sands Capital Management, an asset management firm, since January. Rubin has also completed a fellowship at Harvard Medical School and Massachusetts Eye and Ear Infirmary, where he conducted genetic research in macular degeneration, and has been a resident physician in ophthalmology at the University of Chicago. He holds an MBA from the University of Massachusetts, Amherst, an MD from the University of Chicago Pritzker School of Medicine, and a BS in electrical engineering from the University of California, Los Angeles.
Pacific Biosciences incorrectly stated in an amendment to its S-1 form last month that David Baltimore has joined its board of directors (IS 9/28/2010). In fact, Baltimore has joined the company's scientific advisory board.
Integrated Diagnostics has named Gregory Critchfield to its board of directors as an independent director. Critchfield was the president of Myriad Genetic Laboratories for 12 years until he retired in 2010. He has also served as Quest Diagnostics' chief medical and science officer and as an independent director for BioTrove, a venture-backed molecular biological tools company.
The board of directors at Integrated Diagnostics also includes David Barker, former chief scientific officer at Illumina, as chair; Jim Heath, co-founder of Integrated Diagnostics; Lee Hood, co-founder of Integrated Diagnostics; Patrizia Luchetta, chair of BTC Luxembourg and head of the life sciences and technologies department at the Ministry of the Economy and Foreign Trade, Grand Duchy of Luxembourg; Albert Luderer, CEO of Integrated Diagnostics; and Arnold Oronsky, general partner at InterWest Partners.
The US Senate has confirmed Subra Suresh, President Barack Obama's nominee for director of the National Science Foundation, for a six-year term. Suresh replaces Arden Bement, who led the NSF from 2004 until May, when he resigned.
Prior to his appointment, Suresh served as dean of the engineering school and as Vannevar Bush Professor of Engineering at the Massachusetts Institute of Technology. He was also the head of the materials department at MIT from 2000 to 2006. He holds a bachelor's degree from the Indian Institute of Technology in Madras, a master's degree from Iowa State University, and earned his ScD from MIT.